Early diagnosis value in of serum lysophosphatidic acid and CA-125 detection ovarian cancer
10.3760/cma.j.issn.1008-6706.2009.12.003
- VernacularTitle:血浆溶血磷脂酸和癌抗原125检测在卵巢癌早期诊断中的价值
- Author:
Fengzhen ZHOU
;
Lu LUO
- Publication Type:Journal Article
- Keywords:
Ovarian neoplasms;
Lysophosholipids;
CA-125 antigen
- From:
Chinese Journal of Primary Medicine and Pharmacy
2009;16(12):2117-2118
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical value of early diagnosis of ovarian cancer by serum lysophosphatidic acid(LPA) and CA-125.Methods 50 patients with ovarian cancer from October 2005 to February 2008 were selected as ovarian cancer group,at the same period selected 44 patients with ovarian benign tumor(ovarian benign disease group),and 50 healthy women as the healthy control group.All patients were diagnosed and confirmed by preoperative blood and pathology.The serum LPA and CA-125 of two groups were detected.Results The serum LPA level and the positive rate in the ovarian cancer group was higher than that of the ovaries benign group or the control group(P＜0.05).The CA-125 level in the ovarian cancer group was similar to that of the ovaries benign group(P＞0.05),while the CA-125 level in the ovarian cancer group or the ovaries benign group was higher than that of the control group(P＜0.05).The specificity of the LPA was better than that of the CA-125 detection.In the early diagnosis of ovarian cancer,the sensitivity of the combination(85.7%) was better than either of them(P＜0.01);the plasma LPA level and positive rate of CA-125 of the phase Ⅱ～Ⅳ ovarian cancer patients were higher than that of phase Ⅰ (P＜0.01);the CA-125 positive rate of the serious cystadenocarcinoma was higher than that of the cystadenocarcinoma(P＜0.01).Conclusion LPA is a sensitive biomarker for the early diagnosis of ovarian cancer,especially combined with CA-125.It should be widely used in clinic.
